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The nature of remission
n the field of depression,some distinctions have
been made between various aspects of outcome. An
important paper published in 1991 by Frank et al
1
reviewed these,and assigned operational definitions.
In the short-term outcome,the term remission has usu-
ally been applied to achievement of low or absent symp-
tom levels,representing an end to the immediate episode.
The term recovery has been used to reflect remission
beyond this state,persistent for a longer time period and
more complete.A further term,response,has sometimes
been used,implying considerable improvement,variously
defined,but not necessarily to remission.
Even before recovery is fully achieved, relapse may
occur.Conventionally,relapse in affective disorders has
been used to describe an early return of the depressive
episode after remission,up to approximately 9 months to
a year following the acute episode. This has been
assumed to be a return of the original illness.In part,this
reflects views common in the early days of antidepres-
sants that the disorder is merely suppressed,and that the
underlying disturbance continues until spontaneous
remission occurs.It is difficult to prove this theoretical
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Partial remission from depression, with residual symp-
toms, is an important problem in depression. This paper
reviews the frequency and features of this outcome, and
its association with relapse. Residual symptoms occur in
many depressed patients after acute treatment. They
span the typical symptoms of depression, except those
characteristic of severe disorders. Other persistent abnor-
malities include social dysfunction, dysfunctional atti-
tudes, hypothalamic-pituitary-adrenal axis overactivity,
shortened REM sleep latency, and mood lowering after
tryptophan depletion. Associations of some of these
with residual symptoms are not clear. There is growing
evidence for similar residual symptoms in bipolar disor-
der, particularly bipolar depression. The most important
consequence of residual symptoms is a much-increased
risk of relapse, particularly in the first year. Residual
symptoms are a strong indication for vigorous and
longer than usual continuation of antidepressant treat-
ment, in order to prevent relapse. There is good evi-
dence for the use of cognitive therapy as an adjunct.
© 2008, LLS SAS Dialogues Clin Neurosci. 2008;10:431-437.distinction,other than inferring it from the length of the
symptom-free period. The term recurrence has been
reserved for development of a subsequent episode,
assumed to represent a new episode.
The Frank et al paper gave definitions by severity levels
for presence of an episode,and for remission/recovery.A
later paper from the US
2 has updated the concepts and
definitions.However,missing from the original schema
was consideration of an intermediate state,where remis-
sion might be partial in degree or limited in some aspect,
rather than complete.This has since received consider-
able attention,as it has become apparent that it is a key
pointer to relapse and recurrence.This partial remission
and its consequences are the topic of this paper.
Partial remission and residual symptoms
Our attention was first drawn to the importance of resid-
ual symptoms in a longitudinal follow-up of remission and
relapse in depressed patients treated in Cambridge in the
early 1990s.
3,4A sample of 64 depressed patients meeting
the Research Diagnostic Criteria (RDC) for definite pri-
mary unipolar major depression was identified on presen-
tation,and followed to remission,or for 15 months.Only
4 subjects in the sample of 64 failed to remit to the crite-
rion of 2 months below definite major depression by this
point.However,on examining the findings in more detail,
although the majority of remitters scored in the lower
ranges of the 17-item Hamilton Depression Rating Scale,
an important proportion of 32% (19/60) scored 8 or more
on the Hamilton scale,the criterion proposed by Frank et
al
1 as indicating full remission or recovery.They spanned
a range from 8 to 18,although they did not satisfy the cri-
teria for major depression.
We explored further the nature of these residual symp-
toms by examining individual symptom ratings. The
residual symptoms were those typical of depression,with
ratings at the level of moderate or greater on the
Hamilton scale items of depression,impairment of work
and activities,psychic anxiety,and genital symptoms.The
remaining symptoms were present to at least a mild
degree in most subjects,the exceptions being a group of
symptoms typical of severe depression,such as the fol-
lowing:late insomnia,retardation,agitation,hypochon-
driasis,weight loss,and loss of insight.A parallel set of
analyses carried out on the Clinical Interview for
Depression,
5 which has a wider range of symptom items,
gave similar findings.Depressed mood,guilt,hopeless-
ness, impaired work and interests, psychic anxiety, and
anorexia were prominent.The remaining symptoms were
present to at least a mild degree, except for delayed
insomnia,retardation,agitation,panic attacks,increased
appetite,and depressed appearance.
We also sought predictors of residual symptoms.Using
an extensive set of ratings made at the initial assessment,
we found very few significant predictors.Both reflected
higher initial severity.Patients with residual symptoms
had higher initial scores on the Clinical Interview for
Depression anxiety total score and on the Hamilton scale
17-item total score. Life events, social support, and
expressed emotion did not predict residual symptoms.
We also examined diagnoses made at initial interview on
DSM-III-R criteria for dysthymia.Patients with residual
symptoms were not predominantly previous dysthymics.
Only 11% of those with residual symptoms satisfied
DSM-III-R criteria for dysthymia,as opposed to 17% of
those without residual symptoms.Residual major depres-
sion did not appear to represent return to dysthymia,but
represented a different phenomenon:persistence of the
episode in spite of treatment.
We also examined data which had been collected on drug
treatment and care status,to determine whether deficient
treatment might have been responsible for residual
symptoms.This was not the case.In fact there was a gen-
eral trend for patients with residual symptoms to be
receiving more treatment and care, which would be
expected by good treatment assignment in practice,
based on the presence of symptoms.This does not mean
that higher treatment levels would not be beneficial,but
does indicate that the symptoms were not a consequence
of failure to give standard treatment.
Other studies of residual symptoms
Residual symptoms had received comparatively little
attention prior to this,although they were clearly evident
in the detail of studies,and some aspects had briefly been
reviewed.
6 Clinical experience had also long suggested that
many patients treated initially improved only partially,
leaving residual symptoms which persisted and fluctuated
in the community,causing considerable disability and fam-
ily burden.Because many studies treated these patients
either as nonremitted or as relapsed,their proportion had
not been very well documented.Among inpatients treated
with amitriptyline, approximately one third had been
found to be complete responders,partial responders,and
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7Weissman et al
8 reported a
follow-up study to 4 years in a sample of female depres-
sives who had responded to initial treatment with
amitriptyline and had been included in a controlled trial
of continuation antidepressant and psychotherapy.Many
showed moderate or fluctuating symptoms,corresponding
approximately to residual chronicity,but included some
subjects who relapsed and then remitted.Occurrence of
residual symptoms had been noted in general practice
patients with depression and anxiety,
9 and in 38% of
elderly depressives at 1 year, and 20% at 2 to 4 years.
10
More recently,one or more residual symptoms have been
found in 82% of elderly depression remitters below 8 on
the Hamilton Depression scale.
11At these levels the sub-
jects would be below the usual threshold for partial remis-
sion,however.
More recent studies of residual symptoms have been
reviewed by Fava et al.
12 They have been reported both
after drug treatment and psychotherapy.Fava et al,
13 in a
study of their own,reported a strong relationship between
prodromal and residual symptoms. The most common
symptoms were irritability and anxiety. The influential
Sequenced Treatment Alternatives to Relieve Depression
(STAR*D) study,
14 which has reported higher nonremis-
sion rates for depression than hitherto thought to occur,
did not use a criterion for partial remission.
Residual symptoms and relapse
Following remission, the patients in our original study
4
were followed for another 15 months.As in other follow-
up studies, there was a high rate of subsequent relapse,
with 40% of subjects relapsing over the next 15 months.
All the relapses occurred in the first 10 months, giving
some support to the concept of relapse as an early phe-
nomenon that is distinguished from recurrence later in
time.
An important finding emerged when we separated out the
subjects with residual symptoms at remission. Among
these,76% relapsed in the next 10 months,compared with
25% of subjects without residual symptoms.
3 Residual
symptoms were a key indicator of subsequent relapse.
A number of other studies have drawn attention to high
relapse rates in residual depressives.
10,15-18 One study
19 found
that patients with residual symptoms of depression
obtained greater benefit from maintenance antidepressant
therapy than those who had completely recovered.Prien
and Kupfer
20 found that relapse was less common after full
remission of at least 16 weeks, a finding on which they
based a recommendation that continuation treatment
should comprise at least 4 months of complete remission.
After 9 months,49% of a Dutch sample were found to be
in full remission and 45% in partial remission.
21 Patients
with residual symptoms relapsed early, mainly in the 4
months after remission,while those without these symp-
toms had further episodes later than 1 year.Another study
reported that major depressives with residual symptoms
relapsed three times faster than those without.
22 Residual
symptoms have been found to be a strong predictor of
relapse in primary care depressives.
23 In Spanish outpa-
tients,
24 a relapse rate of 67% was found in the 2 years fol-
lowing partial remission, as opposed to 14% after full
remission.One study
25 attempted to find the best defini-
tion of rating scale scores at 3 or 6 months to predict later
relapse.No precise cutoff score with good sensitivity and
specificity was found,but the higher the score,the greater
the likelihood of relapse.
There has been less study of the association between resid-
ual symptoms at remission and longer-term recurrence,
although some of the above studies fused earlier relapse
and later recurrence in reporting.We
26-28 later extended our
original follow-up study to 10 years.The subjects with pre-
vious residual symptoms spent more time with depressive
symptoms over follow-up,but not more time at full crite-
ria for major depression,and they showed greater impair-
ment in social adjustment.No significant differences were
found between the two groups in percentage recurring
long-term, mean number of recurrences, readmissions,
chronic episodes, or clinical global outcome criteria,
although there were small differences towards worse out-
come on these criteria.The effects of previous residual
symptoms tended to decay over time,and more of the sub-
jects achieved full remission in due course.
In a trial of maintenance imipramine and interpersonal
therapy in patients who had achieved stable remission,the
level of residual symptoms did not predict long-term out-
come, but subjects with greater variability of residual
symptoms had a higher risk of recurrence.
29 In a similar
trial in elderly patients,residual anxiety and residual sleep
disturbance independently predicted early recurrence.
30
Social adjustment
Israel
31 suggested that recovery from depression should
be determined in three domains:symptoms,psychosocial
function,and pathophysiological changes.Social dysfunc-
Partial remission from depression  - Paykel Dialogues in Clinical Neuroscience - Vol 10 . No.4 . 2008
433tion and disability are further additional important con-
sequences of a depressive episode. Social function, or
social adjustment,refers to the function of an individual
within his or her usual environment,and is manifested in
performance and interactions occurring in a variety of
domains including work,leisure activities,or a variety of
roles such as worker,spouse,or parent.Within the hospi-
tal setting,social function has reduced relevance,as the
environment is abnormal and the expectations of role
performance are less,but social function has increased
importance in the outpatient clinic and the community.
Social adjustment was evaluated longitudinally in a sam-
ple of depressed women in New Haven, Connecticut,
USA,in the late 1960s,comparing them with a matched
group of normal subjects in the general population.
32,33
Widespread impairment was found in the depressed
group compared with normal subjects,extending across
all the domains studied,including work,social and leisure
activities,relationships with extended family,marital rela-
tionships,and parental function.These deficits remitted
more slowly than did depressive symptoms,and in the 2-
month time period including response and remission,
these deficits were still severe. Improvement in some
aspects was incomplete even at 8 months.A particularly
marked work impairment was noted.This translates to
decreased productivity and absence from employment,
producing some indirect economic costs of depression.
The problems associated with parental roles are particu-
larly important,since problems in parenting and parent-
child relationships impact on development and later
adaptation of the next generation.
Residual social dysfunction has since been reported by
many other investigators and has been found to correlate
with symptom outcome.Some of the many studies have
been reviewed by Fava et al.
12,34-42
Residual symptoms are associated with increased social
dysfunction. In unpublished data derived from a recent
controlled trial of cognitive therapy in patients with resid-
ual symptoms,
43 mean total scores on the Social Adjustment
Scale were examined at 20 weeks.Both subjects with resid-
ual symptoms at 20 weeks and subjects who had relapsed
by 20 weeks showed worse social adjustment than those
with neither adverse outcome at this point.
Biological and neurocognitive measures
A number of biological and neurocognitive measures
have been found to be abnormal in recovered depres-
sives. These have been reviewed by Bhagwagar and
Cowen.
44 Most prominent have been abnormalities of the
hypothalamic-pituitary-adrenal (HPA) axis, including
waking salivary cortisol
45 and dexamethasone nonsup-
pression.The latter has been found to predict relapse.
Several studies that followed up patients treated with tri-
cyclic antidepressants found that persistent dexametha-
sone nonsuppression at the time of discharge predicted
a greater risk or early relapse.
46-52,53 One study in outpa-
tients
54 and two in patients treated with electroconvulsive
therapy (ECT)
55,56 have failed to find this.The enhanced
dexamethasone-corticotropin-releasing hormone (CRH)
test has also been found to predict relapse.
57
A second group of persistent biological abnormalities is
related to serotonin.The most prominent of these is a
return of depressive symptoms on depletion of trypto-
phan by a high amino-acid drink low in tryptophan.
58A
third group of abnormalities is sleep-related,specifically
persistent shortened REM latency.
59
A further group of abnormalities is neurocognitive.
Particularly prominent are the dysfunctional attitudes
and attributions which occur in depression and have also
been found to persist after symptomatic recovery.
60,61
The relation of these varied abnormalities to residual
symptoms has not been well studied,although they do
appear to occur with full remission.Neither is there good
evidence that they predict relapse,other than for dexam-
ethasone suppression,and REM sleep latency 
Bipolar disorder
This review primarily concerns unipolar disorder.
However, there is a smaller but growing parallel liter-
ature regarding bipolar disorder.Two large prospective
follow-up studies have found subthreshold symptoms
present for substantial periods between episodes,
62,63 as
have a number of smaller studies.
64 Keller et al
65 had
earlier described subsyndromal symptoms in about half
of a sample of bipolar patients in a controlled trial of
high- or low-dose maintenance lithium. Both the large
studies found these to be present for much longer than
the periods of major disorder, and found that depres-
sive symptoms predominated over hypomanic.There
has been less examination of the prediction of major
relapse episodes by these symptoms, but one of the
larger studies
66 found that, when present, these sub-
threshold residual symptoms were strong predictors of
relapse and recurrence.
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residual symptoms
What can be concluded regarding the nature of residual
symptoms? There are various possibilities. Residual
symptoms might represent persistent illness—the origi-
nal illness continuing in milder form.Alternatively,they
might represent the phenomena preceding and underly-
ing the depressive episode.Two possible aspects of the
latter can substantially be discounted:subjects with resid-
ual symptoms are neither liable to be diagnosed as dys-
thymic nor,except to a minor degree,to show more per-
sonality abnormality than those who remit fully.A third
possible underlying phenomenon is that the residual
symptoms could reflect the cognitive vulnerability of dys-
functional attitudes.However,the symptoms shown by
residual depressives,although they include negative cog-
nitions,are not limited to these,but include core mood
and functional symptoms of depression.These are too
wide to be related easily to a single abnormality of low
self-esteem.
It thus seems likely,given these findings,and the relative
lack of association of residual symptoms with anything
else except subsequent relapse,that the explanation is the
first of those given above,persistence of the original dis-
order and its underlying neurobiological substrates.The
most likely conclusion is that residual symptoms are a
manifestation of a disorder which,in spite of improve-
ment,is still present—they are the evidence that the dis-
order continues.This is also supported by the tendency
of relapses following residual symptoms to occur early.
The most important implications of our findings concern
future prognosis and treatment. The association with
relapse argues strongly that residual symptoms should be
treated vigorously,in order to abolish them.Their treat-
ment is dealt with in other papers in this journal issue,
and therefore will not be discussed here.
There are also implications for continuation and mainte-
nance treatment.It is mainly on the basis of the continua-
tion drug trials cited above that a recommendation was
made that continuation treatment should not be with-
drawn until the patient had experienced 4 months free of
all symptoms.
20This may in fact be too early,in the light of
later evidence that the risk of relapse extends longer than
previously thought.
67The presence of residual symptoms
sufficient to indicate incomplete remission should be a
strong indicator for continued treatment until they have
become of minor degree or completely subsided,for about
9 months. Such treatment may include not only antide-
pressants and possibly lithium augmentation,but also cog-
nitive therapy, which has been shown to reduce relapse
rates,
68 including in one study which specifically targeted
relapse-prone subjects with residual symptoms. In this
study,
43,69 we found that adding cognitive therapy to full
doses of antidepressant continuation and maintenance
lowered relapse rates,and the effect lasted for 3 and a half
years after the end of the cognitive therapy. Residual
symptoms at remission also suggest that maintenance anti-
depressant may be required,at least for 2 to 3 years.Such
symptoms also indicate that,when treatment is withdrawn,
withdrawal should be slow.
Conclusion
Partial remission with residual symptoms is an important
outcome of major depression.It probably reflects persis-
tence of the original disorder,in a milder form.It is a key
indicator of much-increased risk of relapse,and the need
for continuing treatment,including antidepressants,and,
in some cases,cognitive therapy. ❏
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Remisión parcial, síntomas residuales y 
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